# Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

> **NCT05251662** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** IBI305
- **DRUG:** GEMOX

## Key facts

- **NCT ID:** NCT05251662
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-13
- **Primary completion:** 2024-01-13
- **Final completion:** 2025-01-13
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05251662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05251662, "Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05251662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*